Rejected biosimilars: the Alpheon case

Biosimilars/Research | Posted 30/07/2009 post-comment0 Post your comment

On 28 June 2006 the Committee for Medicinal Products for Human Use (CHMP) of the EMEA recommended the refusal of marketing authorisation for Alpheon (interferon alfa-2a), which was intended for the treatment of adult patients with chronic hepatitis C in combination with the antiviral medicine ribavirin (except when patients could not take this).

Alpheon had been designed to become a biosimilar medicine of the reference product Roferon-A from F Hoffmann-La Roche and was developed by BioPartners GmbH, based in Baar, Switzerland (acquired by Bioton SA, Poland, in March 2007). Alpheon was manufactured under contract by Rentschler Biotechnologie GmbH & Co KG by expression in recombinant Escherichia coli-bacteria.

BioPartners filed many quality and clinical comparability studies to the EMEA-CHMP. These included comparability studies to Roferon-A on the structure of its active pharmaceutical ingredient, the composition and purity of the medicine, the way it works, the safety and its effectiveness against hepatitis C in 455 patients, measuring how many patients responded to Alpheon after 12 out of the 48 weeks of treatment and six months after stopping treatment.

However, the CHMP had major concerns regarding the comparability of Alpheon and Roferon-A because of differences identified between the two medicines, such as impurities. They also had concerns that there was not enough data on the stability of the active pharmaceutical ingredient and of the medicine that was going to be marketed. Also, the process used for making the finished medicine had not been adequately validated.

The number of patients with hepatitis C responding to treatment with Alpheon and Roferon-A was similar in the clinical study. However, some differences were seen between the two medicines: more patients experienced a return of the disease after treatment with Alpheon was stopped than with the reference medicine, and there were more side effects with Alpheon. In addition, the test used in the study to investigate the potential for the medicine to trigger an immunological response had not been sufficiently validated.

At this point in time, the CHMP was of the opinion that Alpheon could not be considered as a biosimilar medicine of Roferon-A. Hence, it recommended that Alpheon be refused marketing authorisation. Currently, there are no ongoing clinical trials or compassionate use programmes with the product in the EU, but BioPartners still plans to re-file Alpheon.

Source: EMEA, Biopharma, BioPartners

comment icon Comments (0)
Post your comment
Related content
Biosimilars: Promises made. Promises kept?
ST002293
Biosimilars/Research Posted 19/11/2021
Most viewed articles
About GaBI
Home/About GaBI Posted 05/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
Home/Guidelines Posted 08/10/2010